Biocon Limited, has received the Drug Controller General of India’s (DCGI) approval to market ‘Itolizumab,’ a drug previously used to treat chronic plaque psoriasis, for restricted emergency use on COVID-19 patients.
Used to treat rheumatoid arthritis, #Tocilizumab got the green light because of its ability to lower the inflammatory overreaction of the human immune system, which leads to death in infected patients.
/english-betterindia/media/post_attachments/uploads/2020/07/Biocon.jpg)
/english-betterindia/media/post_attachments/uploads/2020/05/Medanta-Feature.jpg)